



**This document was valid from May 2008 until May 2014.
It is now superseded by a [new version](#) adopted by the HMPC on
6 May 2014 and published on the EMA website.**

London, 11 July 2008
Doc. Ref: EMEA/HMPC/262640/2007

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC)

LIST OF REFERENCES SUPPORTING THE ASSESSMENT REPORT ON:

Lupuli flos
***Humulus lupulus* L., flos**
(hop strobiles)

The EMEA acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Abourashed EA, Koetter U, Brattström A. *In vitro* binding experiments with a valerian, hops and their fixed combination extract (Ze91019) to selected central nervous system receptors. *Phytomedicine* 2004; 11: 633-638.

Anonymous. Beilstein Database (Beilstein-Institut zur Förderung der Chemischen Wissenschaften) ; Accessed November 2003.

Anonymous. European Pharmacopoeia, Fifth ed. Council of Europe, Strasbourg, 2004.

Anonymous. Harvard Medical School, 2003b.

Anonymous. *Humulus lupulus*. Monograph. *Alternat Med Rev* 2003a; May: 8(2): 190-192.

Avula B, Ganzera M, Warnick JE, Feltenstein MW, Sufka KJ, Khan IA. High-performance liquid chromatography determination of xanthohumol in rat plasma, urine, and fecal samples. *J Chromatogr Sci* 2004; 42(7): 378-382.

Bednar IJ, Zenisek A. Identification of estrogenic activity of hops. *Brauwissenschaft* 1961; 14: 4-7.

Belgian legislation on herbals : MB 25/02/2005.

Blumenthal M. (Ed.). Herbal medicine : Expanded commission E monographs, first ed. Integr Med Comm, Newton, MA, 2000.

Bouchardy M. A pharmacological study of the action of lupulin and orange flowers on fish. *Pharm Acta Helv* 1953; 28: 183-206.

Bovee TFH, Helsdingen RJR, Rietjesn I, Keijer J, Hoogenboom R. Rapid yeast estrogen bioassays stably expressing human estrogen receptors alpha and beta, and green fluorescent protein: a comparison of different compounds with both receptor types. *J Steroid Biochem Mol Biol* 2004; 91: 99-109.

Bracke et al., 2006, in preparation.

Bradley PR. (ed.) Hops. British Herbal Medicine Association, Dorset 1992: 128-130.

Brattström A. Scientific evidence for a fixed extract combination (Ze 91019) from valerian and hops traditionally used as a sleep-induced aid. *Wien Med Wochenschr* 2007; 157/13-14: 367-370.

Brattström A. Wirksamkeitsnachweis von Phytopharmaka am Beispiel einer Hopfen-Baldrian-Kombination *Forsch Komplementärmed* 1996; 3: 188-195.

Bravo L, Cabo J, Fraile A, Jimenez J, Villas A. Estudio farmacodinamico del lupulo (*Humulus lupulus* L.) action tranquilizante. *Bull Chim Farm* 1974; 113: 310-315.

British Herbal Pharmacopoeia. *Humulus*. British Herbal Medicine Association, London, 1976: 111a.

Butterweck V, Brattstroem A, Grundmann O, Koetter U. Hypothermic effects of hops are antagonized with the competitive melatonin receptor antagonist luzindole in mice. *J Pharm Pharmacol* 2007; 59: 549-552.

Casaschi A, Maiyoh GK, Rubio BK, Li RW, Adeli K, Theriault AG. The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. *J Nutrition* 2004,134, (6) ; 1340-1346.

Caujolle F, Pham Huu Chanh, Duch-Kan P, Bravo Diaz L. Etude de l'action spasmolytique du houblon (*Humulus lupulus*, Cannabinacées). *Agressologie* 1969; 10: 405-410.

Chadwick LR, Pauli GF, Farnsworth NR. The pharmacognosy of *Humulus lupulus* L. (hops) with the emphasis on estrogenic properties. *Phytomedicine* 2006; 13(1-2): 119-131.

Christoffel J, Rimoldi G, Wuttke W. Effects of 8-prenylnaringenin on the hypothalamo-pituitary-uterine axis in rats after 3-month treatment. *J Endocrinol* 2006; 188(3): 397-405.

Chury J. Experimental contribution to the chromatographic separation of sexually active substances in plant extracts. *Sb Vys Sk Zemedel Brne Rada B* 9, 1961: 411-419 (Chem. Abstr 55, 55060).

Coldham NG, Horton R, Byford MF, Sauer MJ. A binary screening assay for pro-estrogens in food: metabolic activation using hepatic microsomes and detection with oestrogen sensitive recombinant yeast cells. *Food Addit Contam* 2002; 19: 1138-1147.

Coldham NG, Sauer MJ. Identification, quantitation and biological activity of phytoestrogens in a dietary supplement for breast enhancement. *Food Chem Toxicol* 2001; 39: 1211-1224.

Cos P, De Bruyne T, Apers S, Berghe DV, Pieters L, Vlietinck AJ. Phytoestrogens: Recent developments. *Planta Med* 2003; 69: 589-599.

Culbreth DMR. In: Hop NF (Ed.) *Manual of Materia Medica and Pharmacology*. Lea and Febiger, Philadelphia, 1927.

De Cooman L, Everaert E, De Keukeleire D. Quantitative analysis of hop acids, essential oils and flavonoids as a clue to the identification of hop varieties. *Phytochem Anal* 1998; 9: 145-150.

De Keukeleire D, De Cooman L, Rong H, Heyerick A, Kalita J, Milligan SR. Functional properties of hop polyphenols. In: Gross GG, Hemingway RW, Yoshida T, editors. *Plant Polyphenols. 2: Chemistry, Biology, Pharmacology, Ecology*. New York: Kluwer Academic/Plenum Publishers, 1999: 739-760.

De Keukeleire D, Milligan SR, De Cooman L, Heyerick A. The oestrogenic activity of hops (*Humulus lupulus* L.) revisited. *Pharm Pharmacol Lett* 1997; 2/3: 83-86.

De Keukeleire D, Milligan SR, Kalita JC, Pocock V, De Cooman L, Heyerick A, Rong H, Roelens F. Prenylated flavonoids are key agents in relation to health-beneficial properties of beer. *Proceedings of the 28th International Congress of the European Brewery Convention, Budapest, Hungary, 2001.*

De Keukeleire D., Heyerick,A., Prenylflavonoids account for intriguing biological activities of hops; *Proc.1st IS on Humulus*, Eds. Hummer,K.E. and Henning,J.H., *Acta Hort.*, 668, ISHS, 2005.

Decroos K, Vanhemmens S, Cattoir S, Boon N, Verstraete W. Isolation and characterisation of an equol-producing mixed microbial culture from a human faecal sample and its activity under gastrointestinal conditions. *Arch Microbiol* 2005; 183: 45-55.

Diel P, Thomae RB, Caldarelli A, Zierau O, Kolba S, Schmidt S, Schwab P, Metz P, Vollmer G. Regulation of gene expression by 8-prenylnaringenin in uterus and liver of Wistar rats. *Planta Med* 2004; 70: 39-44.

Dietz B, Kung YH, Liu G, Egger AL, Yao P, Chadwick LR, Pauli GF, Farnsworth NR, De Mesear RB, van Breemen RB, Bolton JL. Xanthohumol isolated from *Humulus lupulus* inhibits menadion-induced DNA damage through induction of quinone-reductase. *Chem Res Tox* 2005; 18: 1296-1305.

Dixon-Shanies D, Shaikh N. Growth inhibition of human breast cancer cells by herbs and phytoestrogens. *Oncol Rep* 1999; 6: 1383-1387.

Donsback KM. Herbs Book No. 1. Institute for Natural Health Sciences, Huntington Beach, CA, 1977.

Effenberger KE, Johnson SA, Monroe DG, Spelsberg TC, Westendorf JJ. Regulation of osteoblastic phenotype and gene expression by hop-derived phytoestrogens. *J Ster Bioch Mol Biol* 2005; 96: 387-399

Eri S, Khoo BK, Lech J, Hartman TG. Direct thermal desorption-gas chromatography and gas chromatography-mass spectrometry profiling of hop (*Humulus lupulus* L.) essential oils in support of varietal characterization. *J Agric Food Chem* 2000; 48: 1140-1149.

Erkolla R, Vervarcke S, Hurskainen P, Heyerick A, De Keukeleire D. A randomized, double-blind, cross-over study on the use of a standardized hop extract to alleviate menopausal discomforts (in preparation).

ESCOPE Monographs Second ed., Thieme Verlag, 2003, Monograph of the Commission E, BAnz 1984.

Estrada J, Gozala F, Cecchini L, Casquette E. Contact urticaria from hops (*Humulus lupulus*) in a patient with previous urticaria-angioedema from peanut, chestnut, and banana. *Contact Dermat* 2002; 46: 127.

Farnsworth NR (Ed). Napralert®: A database of world literature of natural products. Program for collaborative research in the pharmaceutical sciences, College of Pharmacy, University of Illinois at Chicago, 2003.

Fenselau C, Talahay P. Is oestrogenic activity present in hops? *Food Cosmet Toxicol* 1973; 11: 597-603.

Finn CA, Publicover M. Hormonal control of cell death in the luminal epithelium of the mouse uterus. *J Endocrin* 1981; 91: 335-340.

Flesch P. Hopfen-Baldrian-Kombination als Benzodiazepin-Ersatz? *Geriatric Praxis* 1, 1997 (suppl.) 21-23.

Fluckiger FA, Hanbury D. *Strobili humuli*. In: Pharmacographia. MacMillan & Co, London, 1879.

Füssel A, Wulf A, Brattström, A. Effect of a fixed valerian-hop extract combination (ZE91019) on sleep polygraphy in patients with non-organic insomnia: a pilot study. *Eur J Med Res* 2000; 18(5): 385-390.

Gathercoal EN, Wirth EH. *Humulus*, N.F. in: Pharmacognosy. Lea and Febiger, Philadelphia, 1936.

Gerhauser C, Alt A, Eldeen AG, Neumann I, Frank N, Chmiel H, Bartsch H, Becker H. Antioxidant and radical-scavenging potential of phenolic constituents of beer. *Proc Am Assoc Cancer Res*, 2001b; 42: 18.

Gerhauser C, Alt A, Heiss E, et al. Cancer chemopreventive activity of xanthohumol, a natural product derived from hop. *Mol Cancer Ther* 2002; 1: 959-969.

Gerhauser C, Alt A, Klimo K, Heiss E, Gamal-Eldeen A, Neumann I, Knauff J, Scherf H, Frank N, Bartsch H, Becker H. Xanthohumol from hop (*Humulus lupulus*) as a novel potential cancer chemopreventive agent. Proc Am Assoc Cancer Res 2001a; 42: 19.

Gerhauser C, Frank N. Xanthohumol, a new all-rounder? Molec Nutr & Food Res 2005, September; 49(9): 821-823.

Goetz P. Traitement des bouffées de chaleur par insuffisance ovarienne par l'extract de houblon (*Humulus lupulus*). Revue de Phytoth Prat 1990 ; 4 : 13-15.

Göggelmann W, Schimmer O. Mutagenic activity of phytotherapeutical drugs. In: Knudsen I, editor. Genetic Toxicology of the Diet. New York : Alan R. Liss, 1986; 63: 72.

Grange JM, Davey RW. Detection of antituberculous activity in plant extracts. J Appl Bacteriol 1990; 68: 587-591.

Greenish HC. Hops. In: A Text Book of Materia Medica J & A. Churchill, London, 1909.

Grès MC, Julian B, Bourrié M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G. Correlation between oral drug absorption in humans and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 1998; 15: 726-733.

Grumbach P, Mirimanoff A. The pharmacological determination of lupulin. Bull Soc Pharm 1955; 94: 186-202.

Grundmann O, Brattström A, Koetzer U, Butterweck V. Hypothermic effects of hops could antagonise with the competitive melatonin receptor antagonist luzindole. Planta Medica 2006; (11): 1065, 281.

Guo J, Nikolic D, Chadwick LR, Pauli GF, van Breemen RB. Identification of human hepatic cytochrome P450 enzymes involved in the metabolism of 8-prenylnaringenin and isoxanthohumol from hops (*Humulus lupulus* L.). Drug Metab Dispos 2006, 34 (7); 1152-1159.

Hagers Handbuch der Pharmazeutische Praxis, Hrsg. Hänsel R, Keller K, Rimpler H, Schneider G, Springer Verlag 1993: 447-458.

Hänsel R, Schulz J. Hopfen und Hopfenpräparate: Fragen zur pharmazeutischen Qualität. Dtsch Apoth Ztg 1986 ; 126 : 2033-2037.

Hänsel R, Wagener HH. Versuche, sedative-hypnotische Wirkstoffe in Hopfen nachzuweisen. Arzneim-Forsch/Drug Res 1967; 17: 79-81.

Hänsel R, Wohlfart R, Coper H. Versuche, sedativ-hypnotische Wirkstoffe im Hopfen nachzuweisen. II. Narcotic action of 2-methyl-3-butene-2-ol, contained in the exhalation of hops. Z Naturforsch 1980; 35c: 1096-1097.

Hänsel R, Wohlfart R, Schmidt H. Nachweis sedativ-hypnotischer Wirkstoffe im Hopfen. 3. Mitteilung : Der Gehalt von Hopfen und Hopfenzubereitungen an 2-Methyl-3-buten-2-ol. Planta Med 1982; 45: 224-228.

Hänsel RV, Schulz J. Desmethylxanthohumol: Isolierung aus Hopfen und Cyclisierung zu Flavanonen. Arch Pharm Weinheim 1988; 321: 37-40.

Henderson MC, Miranda CL, Stevens JF, Deinzer ML, Buhler DR. *In vitro* inhibition of human P450 enzymes by prenylated flavonoids from hops, *Humulus lupulus*. Xenobiotica 2000; 30: 235-251.

Hensyl WR. Stedman's Medical Dictionary. Williams & Wilkins, Baltimore, MD, 1990.

Heyerick A, Vervarcke S, Depypere H, Bracke M, De Keukeleire D. A first prospective, randomized, double-blind placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomfort. Maturitas 2006; 54: 169-175.

Hölz J. Inhaltsstoffe des Hopfens (*Humulus lupulus* L.). Z Phytother 1992 ; 13 : 155-161.

Hop Strobile – *Lupuli flos*, in : European Pharmacopoeia, Council of Europe, Strasbourg, France, 3rd ed., suppl. 2000, 795.

Hümpel M, Isaksson P, Schaefer O, Kaufmann U, Ciana P, Maggi A, Schleuning WD. Tissue specificity of 8-prenylnaringenin : Protection from ovariectomy induced bone loss with minimal trophic effects on the uterus. *J Steroid Biochem Mol Biol* 2005; 97: 299-305.

Kitaoka M, Kadokawa H, Sugano M, Ichikawa K, Taki M, Takaishi S et al. Prenylflavonoids : a new class of non-steroidal phytoestrogens (Part 1). Isolation of 8-isopentenylnaringenin and an initial study on its structure-activity relationship. *Planta Med* 1998; 64: 511-515.

Koch W, Heim G. Östrogene hormone in Hopfen und Bier. *Münch Med Wochenschr* 1953; 95: 845.

Koetter U, Schrader E, Käufeler R, Brattström A. A randomized, double-blind, placebo-controlled, prospective clinical study to demonstrate clinical efficacy of a fixed valerian hops extract combination (Ze 91019) in patients suffering from non-organic sleep disorder. *Phytother Res* 2007; 21: 847-851.

Kondo K. Preventive effects of dietary beer on lifestyle-related diseases. 29th International Congress of the European Brewery Convention, Dublin, Ireland, 17-22 May 2003, CD-ROM of Proceedings.

Kumai A, Okamoto R. Extraction of the hormonal substance from hops. *Toxicol Lett*, 1984; 21: 203-207.

Langezaal CR, Chandra A, Scheffer JJ. Antimicrobial screening of essential oils and extracts of some *Humulus lupulus* L. cultivars. *Pharm Weekbl Sci* 1992; 14: 353-356.

Lanzotti B, Souza G, Sarti S, Filho D, Ferreira S. Myrcene mimics the peripheral anagesic activity of lemongrass tea. *J Ethnopharmacol* 1991; 34: 43-48.

Lataster MJ, Brattström A. Die Behandlung von Patienten mit Schlafstörungen. Wirksamkeit und Verträglichkeit von Baldrian-Hopfen-Dragees. *notabene medici* 1996; 4: 182-185.

Laughin, G.A., Barrett-Conner, E., Criqui, M.H., Kritiz-Silverstein, D., The prospective association of serum insuline-like growth factor I(IGF-I) and IGF-binding protein-1 levels with all – cause and cardiovascular diseases mortality in older adults, The Racho Study, *J.Clin.Endocrinol.Metabol.*, 2004, 89, 114-120.

Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extracts of valerian root (*Valeriana officinalis* L.) improves sleep quality in man. *Pharmacol Biochem Behav* 1982; 17: 67-71.

Lee KM, Jung JS, Song DK, Kim YH. Neuropharmacological activity of *Humulus lupulus* extracts. *Korean J Pharmacogn* 1993b; 24: 231-234.

Lee KM, Jung JS, Song DK, Krauter M, Kim YH. Effects of *Humulus lupulus* extract on the central nervous system in mice. *Planta Med* 1993a; 59 (Suppl): A691.

Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HHS, Farnsworth NR, Bolton JL. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. *J Agric Food Chem* 2001; 49: 2472-2479.

Maisch JM. *Humulus*. In: Organic Materia Medica, Lea Brothers & Co., Philadelphia, 1892.

Matos R, Vasconcelos L, Oleastro M, Monterio L. Antibacterial activity of *Humulus lupulus* against *Helicobacter pylori*. *Gut* 2001; 49 (Suppl. 1): A5.

McMurrough I. High-performance liquid chromatography of flavonoids in barley and hops. *J Chromatogr* 1981; 316: 132-137.

Meissner O, Häberlein H. Influence of xanthohumol on binding behaviour of GABA_A receptors and their lateral mobility at hippocampal neurons. *Planta Medica* 2006; 72: 656-68.

Meyer J. Hops. In: The Herbalist. Clarence Meyer, self published, 1960.

- Miller CE, Schumacher B, Brattström A, Abourashed EA, Koetter E. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. *Life Sciences* 2002; 71(16): 1939-1949.
- Milligan S, Kalita J, Pocock V, Heyerick A, De Cooman L, Rong H, De Keukeleire D. Oestrogenic activity of the hop phyto-oestrogen, 8-prenylnaringenin. *Reproduction*. 2002; 123: 235-242.
- Milligan SR, Kalita JC, Heyerick A, Rong H, De Cooman L, De Keukeleire D. Identification of a potent phytoestrogen in hops (*Humulus lupulus* L.) and beer. *J Clin Endocrinol Metab* 1999; 84: 2249-2252.
- Milligan SR, Kalita JC, Pocock V, Van De Kauter V, Stevens JF, Deinzer ML, Rong H, De Keukeleire D. The endocrine activities of 8-prenylnaringenin and related hop (*Humulus lupulus* L.) flavonoids. *J Clin Endocrinol Metab* 2000; 85: 4912-4915.
- Millspaugh CM. *Lupulus*. In: *American Medicinal Plants*, Dover, San Fransisco, CA, 1974.
- Miranda CL, Aponso GLM, Stevens JF, Deinzer ML, Buhler DR. Prenylated chalcones and flavanones as inducers of quinone reductase in mouse Hepa 1x1C7 cells. *Cancer Lett* 2000b; 149: 21-29.
- Miranda CL, Stevens JF, Helmrich A, Henderson MC, Rodriguez RJ, Yang YH et al. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (*Humulus lupulus*) in human cancer cell lines. *Food Chem Toxicol* 1999; 37: 271-285.
- Miranda CL, Stevens JF, Ivanov V, McCall M, Frei B, Deinzer ML, Buhler DR. Antioxidant and prooxidant actions of prenylated and nonprenylated chalcones and flavanones *in vitro*. *J Agric Food Chem* 2000c; 48: 3876-3884.
- Miranda CL, Yang YHA, Henderson MC, Rodriguez RJ, Yang Y-H, Deinzer ML, Barnes DW, Buhler DR. Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo (4,5-F) quinoline, mediated by cDNA-expressed human CYP1A2. *Drug Metab Disp* 2000a; 28: 1297-1302.
- Mitchell J, Rook A. *Botanical Dermatology Plants and Plant products injurious to the skin*. Vancouver: Greengrass, 1979, from *Herbal Medicines: A guide for health-care professionals*, Newall CA, Anderson LA, Philipsson JD, The Pharmaceutical Press, London, 1996: 162-163.
- Miyamoto M, Matsushita Y, Kiyokawa A, Fukuda C, Iijima Y, Sugano M, Akiyama T. Prenylflavonoids: a new class of non-steroidal phytoestrogen (part 2). Estrogenic effects of 8-isopentenylnaringenin on bone metabolism. *Planta Med* 1998; 64: 516-519.
- Mizobuchi S, Sato Y. A new flavanone with antifungal activity isolated from hops. *Agric Biol Chem* 1984; 48: 2771-2775.
- Morali G, Polatti F, Metilitser EN, Mascarucci P, Magnani P, Marzé PB. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. *Arzneimittelforsch* 2006; 56(3): 230-238.
- Morin CM, Koetter U, Bastien C, Wane JC, Wooter V. Valerian-hops combination and diphenhydramine for treating insomnia : a randomised placebo-controlled clinical trial. *Sleep*, 2005; 28(11): 1465-1471.
- Mueller CE, Schumacher R, Brattström A, Abourashed EA, Koetter E. Interactions of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. *Life Sciences* 2002; 71(16): 1939-1949.
- Mueller-Limmroth W, Ehrenstein W. Experimental studies of the effects of Seda-Kneipp on the sleep of sleep disturbed subjects: implications of the treatment of different sleep disturbances. *Med Klin* 1977; 72: 1119-1125.
- Munch JC, Pratt HJ, de Ponce AM. Quantitative applications of the modified Türk test. *J Am Pharm Assoc* 1933; 22: 1078-1080.

Newal AC, Anderson LA, Phillipson JD. Hops. Herbal Medicines. A guide for healthcare professionals. 1st Ed. Pharmaceutical Press, London, Chicago 1996: 162-163.

Newark FM. Hops allergy and terpene sensitivity: an occurred disease. Am Allergy 1978; 41:311-312.

Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-like growth factor I (IGF-I) and IGF-binding protein-1 modulate prostate cancer cell growth and apoptosis: Possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 2003; 144: 2319-2324.

Nikolic D, Li Y, Chadwick LR, Grubjesic S, Schwab P, Metz P, van Breemen RB. Metabolism of 8-prenylnaringenin, a potent phytoestrogen from hops (*Humulus lupulus* L.), by human liver microsomes. Drug Metab Dispos 2004; 32: 272-279.

Nikolic D, Li Y, Chadwick LR, Pauli GF, van Breemen RB. Metabolism of xanthohumol and isoxanthohumol, prenylated flavonoids from hops (*Humulus lupulus* L.), by human liver microsomes. J Mass Spectrom 2005; 40: 289-299.

Nikolic D, Li Y, Chadwick LR, van Breemen RB. *In vitro* studies of intestinal permeability and hepatic and intestinal metabolism of 8-prenylnaringenin, a potent phytoestrogen from hops (*Humulus lupulus* L.). Pharm Res 2006; 23, (5): 864-872.

Nookandeh A, Frank N, Steiner F, Ellinger R, Schneider B, Gerhauser C, Becker H. Xanthohumol metabolites in faeces of rats. Phytochemistry 2004; 65: 561-570.

Notox B.V., Safety and Environmental Research, Hertogenbosch, The Netherlands, Toxicological Report 2005.

Notter D, Brattström A, Morandell D, Polasek W. Wirksamkeit und Sicherheit eines Baldrian-Hopfen-Kombinationspräparates bei verschiedenen Schlafstörungen. Phytotherapie 2003; 3: 9-12.

Obourn, J.D., Koszewski, N.J., Notides, A.C., Hormone- and DNA-binding mechanisms of the recombinant human estrogen receptor, Biochemistry 1993; 32: 6229-6236.

Ohsugi M, Basnet P, Kadota S, Ishii E, Tamura T, Okumura Y, Namba T. Antibacterial activity of traditional medicines and an active constituent lupulone from *Humulus lupulus* against *Helicobacter pylori*. J Trad Med 1997; 14: 186-191.

Okamoto R, Kumai A. Antigonadotrophic activity of hop extract. Acta Endocrinol 1992; 127:371-377.

Ososki AL, Kenelly EJ. Phytoestrogens : a review of the present state of research. Phytotherapy Res 2003; 17: 845-869.

Overk CR, Yao P, Chadwick LR, Nikolic D, Sun YK, Cuendet MA, Deng YF, Hedayatt AS, Pauli GF, Farnworth N.R., von Breemen RB, Bolton JL. Comparison of the *in vitro* estrogenic activities of compounds from hops (*Humulus lupulus*) and red clover (*Trifolium pratense*). J Agric Food Chem 2005; 53: 6246-6253.

Pepper MS, Hazel SJ, Hümpel M, Schleunig W-D. 8-Prenylnaringenin, a novel phytoestrogen inhibits angiogenesis *in vitro* and *in vivo*. J Cell Physiol 2004; 199: 98-107.

Possemiers S, Bolca S, Grootaert C, Heyerick A, Decroos K, Dhooge W, De Keukeleire D, Rabot S, Verstraete W, Van de Wiele T. The prenylflavonoid isoxanthohumol from hops (*Humulus lupulus* L.) is activated into the potent phytoestrogen 8-prenylnaringenin *in vitro* and in the human intestine. J Nutr, 2006; 136 (7): 1862-1867.

Possemiers S, Heyerick A, Robbens V, De Keukeleire D, Verstraete W. Activation of proestrogens from hops (*Humulus lupulus* L.) by intestinal microbiota. Conversion of isoxanthohumol into 8-prenylnaringenin. J Agricul and Food Chem 2005; 53: 6281-6288.

Racz G, Fazakas B, Racz-Kotilla E. Trichomonazide und anthelminthische Wirkung in der rumanischen Volksmedizin verwendeten Pflanzen. Planta Med 1980; 39: 257.

Rad M, Hümpel M, Schaefer O, Schoemaker RC, Schleuning WD, Cohen AF, Burggraaf S. Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. *Br J Clin Pharm*, 2006; 62(3): 288-296.

Rao V, Menezes A, Viana G. Effect of myrcene on nociception in mice. *J Pharm Pharmacol* 1990; 42: 877-878.

Rauha J-P, Tammela P, Summanen J, Vuorela P, Kähkönen M, Heinonen M et al. Actions of some plant extracts containing flavonoids and other phenolic compounds on calcium fluxes in clonal rat pituitary GH₄C₁ cells. *Pharm Pharmacol Lett* 1999; 9: 66-69.

Rodenbeck A, Hajak G. Polysomnographische Pilotstudie zur Wirkung von Hopfen/Baldrian auf den Schlaf von Patienten mit primärer Insomnie. Eine doppelblinde, randomisierte, placebokontrollierte Studie im Schlaflabor, 1998, Study Report MI 9221.

Rong H, Boterberg T, Maubach J, Stove C, Depypere H, Van Slambrouck S, Serreyn R, De Keukeleire D, Marlee M, Bracke M. 8-Prenylnaringenin, the phytoestrogen in hops and beer, upregulates the function of the E-cadherin/catenin complex in human mammary carcinoma cells. *Eur J Cell Biol* 2001; 80: 580-585.

Rong H, Zhao Y, Laou K, De Keukeleire D, Milligan SR, Sandra P. Quantitation of 8-prenylnaringenin, a novel phytoestrogen in hops (*Humulus lupulus* L.), hop products and beers, by HPLC-MS using atmospheric pressure electrospray ionization. *Chromatographia* 2000; 51: 545-552.

Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A. Bioavailability of phyto-oestrogens. *Br J Nutr* 2003; 89: S45-S58.

Schaefer O, Bohlmann R, Schleuning WD, Schulze-Forster K, Hümpel M. Development of a radioimmunoassay for the quantitative determination of 8-prenylnaringenin in biological matrices. *J Agric and Food Chem* 2005; 53: 2881-2889.

Schaefer O, Hümpel M, Fritzscheier KH, Bohlmann R, Schleuning WD. 8-Prenylnaringenin is a potent ER alpha selective phytoestrogen present in hops and beer. *J Steroid Biochem and Mol Biol* 2003; 84: 359-360.

Schaefer O. Untersuchungen zum Phytoestrogen 8-prenylnaringenin aus Hopfen für den Einsatz in der Hormon-Ersatz-Therapie. Universität Hannover, Ph D Thesis, 2004.

Schellenberg A, Sauer S, Abourashed EA, Koetter U, Brattström A. The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism. *Planta Med* 2004; 70: 694-697.

Schiller H, Forsten A, Vonhoff C, Hegger M, Biller A, Wintershoff H. Sedating effects of *Humulus lupulus* L. extracts. *Phytomedicine* 2006; 13: 535-541.

Schleif W, Galludet BB. *Humulus*, US. In: *Materia Medica, Therapeutics, Pharmacology and Pharmacognosy*, Lea Brothers & Co., Philadelphia, 1907.

Schmalreck AF. Structural features determining the antibiotic potencies of natural and synthetic hop bitter resins, their precursors and derivatives. *Can J Microbiol* 1975; 21: 205-212.

Schmitz M, Jäckel M. Comparative study for assessing quality of life of patients with exogenous sleep disorders (temporary sleep onset and sleep interruption disorders) treated with a hops-valerian preparation and a benzodiazepine drug. *Wien Med Wochenschr* 1998; 148: 291-298.

Schulz J, Hänsel R, Tyler VE. Hop strobiles and hop glands. In: *Rational Phytotherapy*. Springer, Berlin, Germany, 2001.

Shimamura M, Hazato T, Ashino H, Yamamoto Y, Iwasaki E, Tobe H, Yamamoto K, Yamamoto S. Inhibition of angiogenesis by humulone, a bitter acid from beer hop. *Biochem Biophys Res Commun* 2001; 289: 220-224.

Sikorski H, Rusiecki W. The sedative action of various constituents of hops. *Bull Intern Acad Polon Sci Classe Med* 1938; 1936: 73-83 (Chem Abstr 32, 66011).

Simpson WJ, Smith AR. Factors effecting antibacterial activity of hop compounds and their derivatives. *J Appl Bacteriol* 1992; 72: 327-334.

Staven-Groenberg A. Action upon frogs of substances derived from hops. *Arch Exptl Path Pharm* 1928; 123: 272-281 (Chem Abstr 22, 2362).

Steidle H. The pharmacology of hops. *Arch Exptl Path Pharm* 1932; 161: 154-162 (Chem Abstr 26, 26357).

Stevens JF, Ivančić M, Hsu VL, Deinzer ML. Prenylflavonoids from *Humulus lupulus*. *Phytochem* 1997; 44: 1575-1585.

Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! *Phytochem* 2004; 65: 1317-1330.

Stevens JF, Taylor AW, Clawson JE, Deinzer ML. Fate of xanthohumol and related prenylflavonoids from hops to beer. *J Agric Food Chem* 1999a; 47: 2421-2428.

Stevens JF, Taylor AW, Deinzer ML. Quantitative analysis of xanthohumol and related prenylflavonoids in hops and beer by liquid chromatography-tandem mass spectrometry. *J Chromatogr A* 1999b; 832: 97-107.

Strenkovskaya AG. Estrogenic hops extract for cosmetics. Russian Patent 19680530, 1968.

Tabata N, Ito M, Tomoda H, Omura S. Xanthohumols, diacylglycerol acyltransferase inhibitors from *Humulus lupulus*. *Phytochem* 1997; 46: 683-687.

Tagashira M, Uchiyama K, Yoshimura T, Shirota M, Uemitsu N. Inhibition by hop bract polyphenols of cellular adherence and water-insoluble glucan synthesis of *Mutans streptococci*. *Biosci Biotechnol Biochem* 1997; 61: 332-335.

Takamura-Enya T, Ishihara J, Tahara S, et al. Analysis of estrogenic activity of foodstuffs and cigarette smoke condensates using a yeast estrogen screening method. *Food Chem Toxicol* 2003; 41: 543-550.

Teuber M, Schmalreck AF. Membrane leakage in *Bacillus subtilis* 168 induced by the hop constituents lupulone, humulone, isohumulone and humulinic acid. *Arch Mikrobiol* 1973; 94: 159-171.

Tobe H, Kubota M, Yamaguchi M, Kocka T, Aoyagi T. Apoptosis to HL-60 by humulone. *Biosci Biotechnol Biochem* 1997b; 61: 1027-1029.

Tobe H, Muraki Y, Kitamura K, Komiyama O, Sato Y, Sugioka T, Maruyama HB, Matsuda E, Nagai M. Bone resorption inhibitors from hop extract. *Biosci Biotech Biochem* 1997a; 61: 158-159.

Tokalov SV, Henker Y, Schwab P, Metz P, Gutzeit HO. Toxicity and cell cycle effects of synthetic 8-prenylnaringenin and derivatives in human cells. *Pharmacology* 2004; 71: 46-56.

Turner NJ, Thomson BM, Shaw IC. Bioactive isoflavones in functional foods: The importance of gut microflora on bioavailability. *Nutr Rev* 2003; 61: 204-213.

Vanhoecke B, Derycke L, Van Marck V, Depypere H, De Keukeleire D, Bracke M. Anti-invasive effect of xanthohumol, a prenylated chalcone present in hops (*Humulus lupulus* L.) and beer. *Intern J Cancer* 2005; 117(6): 889-895.

Verzele M, De Keukeleire D. Chemistry and analysis of hop and beer bitter acids, Elsevier, Amsterdam, 1991.

Verzele M. Centenary review: 100 years of hop chemistry and its relevance to brewing. *J Inst Brew* 1986; 92: 32-48.

Vonderheid-Guth B, Todovora A, Brattstrom A, Dimpfel W. Pharmacodynamic effects of valerian and hops extract combination (Ze91019) on the quantitative-topographical EEG in healthy volunteers. *Eur J Med Res* 2000; 5: 139-144.

Wang LQ, Meselhy MR, Li Y, Qin GW, Hattori M. Human intestinal bacteria capable of transforming secoisolariciresinol diglucoside to mammalian lignans, enterodiol and enterolactone. *Chem Pharm Bull* 2000; 48: 1606-1610.

Washburn HC, Blome WH. Hops-NF. In: *Pharmacognosy and Materia Medica for Students in Pharmacy and Practicing Pharmacists*. Wiley, New York, NY, 1927.

Wegener T. Phytopharmaka zur Anxiolyse. Zur Wirkung einer Kombination von Baldrian und Hopfen bei Angstzuständen. *Dt Apoth Ztg* 2003; 143: 618-625.

Wilcox RW. Hops. In: *Materia Medica and Therapeutics*. Blakiston's Son & Co., Philadelphia, 1912.

Wohlfart R, Hänsel R, Schmidt H. Nachweis sedativ-hypnotischer Wirkstoffe im Hopfen. 4. Mitteilung : Die Pharmakologie des Hopfeninhaltsstoffe 2-Methyl-3-buten-2-ol. *Planta Med* 1983a; 48: 120-123.

Wohlfart R, Wurm G, Hänsel R, Schmidt H. Nachweis sedativ-hypnotischer Wirkstoffe im Hopfen. 5. Mitteilung : Der Abbau der Bittersäuren zum 2-Methyl-3-buten-2-ol, einem Hopfeninhaltsstoff mit sedativ-hypnotischer Wirkung. *Arch Pharm (Weinheim)* 1983b; 316: 132-137.

Wohlfart R. Humulus. In : Hänsel R, Keller K, Rimpler H, Schneider G, editors. *Hagers Handbuch der pharmazeutischen Praxis*, 5th ed. Volume 5, Drogen E-O. Berlin : Springer-Verlag, 1993 : 447-458.

Wohlfart R. Wirkstoffprobleme des Hopfens. *Z Phytotherapie* 1982; 3: 393-395.

Wren RC. Hops. *Potter's new cyclopedia of botanical drugs and preparations*. Essex, UK: Saffron Waldon, CW. Daniel Co. Ltd., 1989: 146.

Yamamoto K, Wang J, Yamamoto S, Tobe H. Suppression of cyclooxygenase-2 gene transcription by humulon of beer hop extract studied with reference to glucocorticoid. *FEBS Lett* 2000; 465: 103-106.

Yasukawa K, Takeuchi M, Takido M. Humulon, a bitter in the hop, inhibits tumor promotion by 12-*O*-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. *Oncology (Basel)* 1995; 52: 156-158.

Yasukawa K, Yamaguchi A, Arita J, Sakurai S, Ikeda A, Takido M. Inhibitory effect of edible plant extracts on 12-*O*-tetradecanoylphorbol-13-acetate-induced ear oedema in mice. *Phytother Res* 1993; 7: 185-189.

Yilmazer M, Stevens JF, Buhler DR. *In vitro* glucuronidation of xanthohumol, a flavonoid in hop and beer, by rat and human liver microsomes. *FEBS Lett* 2001b; 491: 252-256.

Yilmazer M, Stevens JF, Deinzer ML, Buhler DR. *In vitro* biotransformation of xanthohumol, a flavonoid from hops (*Humulus lupulus*), by rat liver microsomes. *Drug Metab Dispos* 2001a; 29: 223-231.

Youngken HW. *Humulus*. In : *Text-book of Pharmacognosy*. Blakiston Company, Philadelphia, 1950.

Zagari A. *Medicinal plants*, fifth ed. Tehran University Publications, Tehran, Iran, 1992.

Zanoli P, Rivasi M, Zavatti M, Brusiani F, Bardhi M. New insight in the neuropharmacological activity of *Humulus lupulus* L. *J Ethnopharmacol* 2005; 102: 102-106.

Zava, D.T., Dollbaum, C.M., Blen, M. Estrogen and progestin bioactivity of foods, herbs and spices, *Proc.Soc.Exp.Biol.Med.*, 1998; 217: 369-378.

Zemlan FP, Mulchachev JJ, Scharf MB, Magleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist beta-methyl-6-chlormelatonin in primary insomnia: a randomized placebo-controlled, cross-over clinical trial. *J Clin Psychiatry* 2005; 66(3): 384-390.

Zierau O, Gester S, Schwab P, Metz P, Kolba S, Wulf M, Vollmer G. Estrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylallyl)naringenin and 8-prenylnaringenin. *Planta Med* 2002; 68: 449-451.

Zierau O, Hamonn J, Tischer S, Schwab P, Metz P, Vollmer G, Gutzeit HO, Scholz S. Naringenin-type flavonoids show different estrogenic effects in mammalian and teleost test systems. *Biochem Biophys Res Commun* 2005; 326: 909-916.

Zierau O, Hauswald S, Schwab P, Metz P, Vollmer G. Two major metabolites of 8-prenylnaringenin are estrogenic *in vitro*. *J Steroid Biochem and Molec Biol* 2004; 92: 107-110.

Zierau O, Morissey C, Watson RWG, Schwab P, Kolla S, Metz P, Vollmer G. Antiandrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylnaringenin) and 8-prenylnaringenin. *Planta Medica* 2003; 69: 856-858.

Superseded